Advisory Services Network, LLC Supernus Pharmaceuticals, Inc. Transaction History

Advisory Services Network, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$22.72 - $29.68 $1,136 - $1,484	50 New	50 $1,000
Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $1,709 - $2,083	55 New	55 $1,000
Q1 2021 May 24, 2021	SELL	$24.15 - $31.45 $0 - $0	0 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$17.7 - $25.81 $3,964 - $5,781	-224 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $4,524 - $5,611	224 New	224 $5,000
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $346 - $592	-24 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$19.93 - $29.13 $13,552 - $19,808	-680 Reduced 96.59%	24 $1,000
Q2 2019 Aug 01, 2019	BUY	$29.96 - $38.87 $18,695 - $24,254	624 Added 780.0%	704 $0
Q3 2018 Nov 02, 2018	SELL	$42.7 - $56.55 $1,793 - $2,375	-42 Reduced 34.43%	80 $4,000
Q2 2018 Jul 27, 2018	SELL	$44.1 - $59.85 $970 - $1,316	-22 Reduced 15.28%	122 $7,000
Q1 2018 Apr 23, 2018	BUY	$37.15 - $46.9 $928 - $1,172	25 Added 21.01%	144 $0
Q2 2017 Aug 17, 2017	BUY	N/A	119	119 $5,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.